YouTube Facebook LinkedIn Google+ Twitter Xingrss  

What Amgen's deCODE Purchase Means for Drug Discovery


December 10, 2012 | Does Amgen's purchase of deCODE present a model for counteracting failure rates in drug discovery. Terry McGuire points out: "Amgen acquired deCODE for more than its patents, genetic testing business, or drug development projects—although there is plenty of value there. Amgen bought deCODE for its powerhouse research engine." Xconomy
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.